Skip to Content

Triumeq Approval History

  • FDA approved: Yes (First approved August 22nd, 2014)
  • Brand name: Triumeq
  • Generic name: abacavir, dolutegravir and lamivudine
  • Dosage form: Tablets
  • Company: ViiV Healthcare
  • Treatment for: HIV Infection

Triumeq (abacavir, dolutegravir and lamivudine) is a fixed-dose combination containing the INSTI dolutegravir and the NRTIs abacavir and lamivudine for the treatment of HIV-1 infection.

Development History and FDA Approval Process for Triumeq

Aug 22, 2014Approval FDA Approves Triumeq for the Treatment of HIV-1 Infection

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.